FDA approved Keytruda (pembrolizumab) Jan. 8 for the treatment of patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
